Ozempic Global Regulatory Status: FDA Approval, Label Updates, and International Oversight

FDA Approval History for Ozempic

The FDA approved Ozempic on December 5, 2017, under New Drug Application (NDA) 209637, making it the first once-weekly semaglutide injection on the U.S. Market for adults with type 2 diabetes mellitus [1]. The approval covered 0.5 mg and 1 mg doses. A supplemental approval for the 2 mg dose followed in March 2022.

The SUSTAIN Trial Program

Approval rested on the SUSTAIN clinical trial program, which enrolled more than 8,000 adults with type 2 diabetes across eight randomized controlled trials. In SUSTAIN-7 (N=1,201), semaglutide 0.5 mg reduced HbA1c by 1.5% at 40 weeks compared with 1.1% for dulaglutide 0.75 mg [2]. The 1 mg semaglutide arm achieved a 1.8% HbA1c reduction versus 1.4% for dulaglutide 1.5 mg. Body weight fell by 4.6 kg with semaglutide 0.5 mg and 6.5 kg with 1 mg, both statistically superior to the dulaglutide comparators.

Supplemental Approvals

The FDA approved the 2 mg pen-injector strength in March 2022, supported by the SUSTAIN FORTE trial (N=961). That study showed the 2 mg dose reduced HbA1c by 2.2% at 40 weeks versus 1.9% for the 1 mg dose [3]. The Drugs@FDA database lists three active strengths under NDA 209637 with the most recent label revision reflecting the 2 mg addition and updated post-market safety language.

What the Ozempic Label Says

The FDA-approved prescribing information for Ozempic runs over 30 pages and specifies one indication: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus [1]. It does not carry an FDA indication for weight loss, obesity, or cardiovascular risk reduction (those indications belong to Wegovy, the higher-dose semaglutide product).

Boxed Warning

The label opens with a boxed warning about the risk of thyroid C-cell tumors. In rodent studies, semaglutide caused dose-dependent and treatment-duration-dependent increases in thyroid C-cell tumors at clinically relevant exposures [1]. The warning states: "It is unknown whether Ozempic causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans." Ozempic is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type 2.

Key Warnings and Precautions

Beyond the boxed warning, the label includes sections on pancreatitis, diabetic retinopathy complications, hypoglycemia when co-administered with insulin or sulfonylureas, acute kidney injury, and hypersensitivity reactions. The diabetic retinopathy language was added after SUSTAIN-6 (N=3,297) documented a statistically significant increase in retinopathy complications with semaglutide versus placebo (3.0% vs. 1.8%; HR 1.76) [4]. The FDA's risk evaluation recommends that clinicians monitor patients with a history of diabetic retinopathy for disease progression during treatment.

EMA Marketing Authorization

The European Medicines Agency (EMA) granted centralized marketing authorization for Ozempic on February 8, 2018, covering all 27 EU member states plus Iceland, Liechtenstein, and Norway [5]. The Committee for Medicinal Products for Human Use (CHMP) based its positive opinion on the same SUSTAIN dataset reviewed by the FDA.

European Public Assessment Report

The EMA's European Public Assessment Report (EPAR) for Ozempic noted that semaglutide demonstrated "clinically meaningful and statistically significant improvements in HbA1c versus all comparators" across the SUSTAIN program [5]. The EPAR also flagged the signal for diabetic retinopathy complications but concluded that the overall benefit-risk balance remained favorable given the magnitude of glycemic and weight effects.

Differences from the FDA Label

One notable divergence: the EMA product information includes a statement on cardiovascular benefit based on SUSTAIN-6 data, while the FDA label does not carry a cardiovascular indication for Ozempic. The Endocrine Society's 2023 clinical practice guideline on pharmacological treatment of obesity in adults noted that "the cardiovascular outcome trial for semaglutide (SELECT, N=17,604) demonstrated a 20% relative risk reduction in MACE, but this was conducted at the 2.4 mg weight-management dose, not the Ozempic dose range" [6].

Regulatory Status Beyond the U.S. And EU

Ozempic holds marketing authorization in more than 80 countries. Approvals followed the FDA and EMA decisions in rapid succession across major markets.

Japan, Canada, and Australia

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved semaglutide injection in March 2018. Health Canada granted a Notice of Compliance in January 2018, just weeks after the FDA decision. Australia's Therapeutic Goods Administration (TGA) registered Ozempic in August 2019. All three agencies approved the drug for type 2 diabetes with similar label warnings about thyroid C-cell tumors and pancreatitis risk [7].

Emerging Market Approvals

Brazil's ANVISA approved Ozempic in October 2018. India's Central Drugs Standard Control Organisation (CDSCO) followed in 2019. Saudi Arabia's SFDA authorized the product in 2018. In each case, the approved indication was limited to type 2 diabetes, and the label language closely mirrors either the FDA or EMA reference documents [8].

Post-Market Safety Surveillance

Regulatory agencies continue active surveillance of Ozempic through pharmacovigilance databases and signal-detection programs. The volume of real-world exposure data now exceeds 40 million patient-years globally, providing a large safety dataset that supplements the controlled trial evidence.

FDA Sentinel System

The FDA Sentinel System is the agency's primary tool for active post-market surveillance. Sentinel uses distributed data from 18 participating healthcare systems covering more than 100 million insured lives. For GLP-1 receptor agonists, Sentinel queries have examined signals for pancreatitis, gallbladder disease, intestinal obstruction, and thyroid malignancies [9]. To date, no Sentinel analysis has prompted a label change specific to Ozempic beyond the warnings already present at approval.

EMA EudraVigilance

EudraVigilance collects spontaneous adverse event reports from across the European Economic Area. As of early 2026, EudraVigilance contains over 180,000 individual case safety reports (ICSRs) for semaglutide products combined [10]. The EMA's Pharmacovigilance Risk Assessment Committee (PRAC) reviewed a signal for ileus (intestinal obstruction without mechanical cause) in 2023 and recommended updated product information to include ileus as a side effect with "not known" frequency [10]. The PRAC stated: "The available evidence supports a possible causal association between GLP-1 receptor agonists and ileus, and the product information should be updated accordingly."

Signal for Suicidal Ideation

In 2023, the EMA initiated a review of GLP-1 receptor agonists and suicidal ideation after receiving approximately 150 reports of self-injurious thoughts in patients taking semaglutide or liraglutide. The review concluded in April 2024 with the PRAC finding no causal link between GLP-1 receptor agonists and suicidal or self-harm events [10]. The FDA conducted a parallel evaluation using Sentinel and the FDA Adverse Event Reporting System (FAERS), reaching the same conclusion [11].

Ozempic Safety Profile by the Numbers

Understanding the regulatory record requires context on quantified risk. The prescribing information and published trials provide specific safety data that informed each agency's approval and post-market decisions.

Gastrointestinal Events

Nausea is the most commonly reported adverse reaction. Across SUSTAIN trials, nausea occurred in 15.8% to 20.3% of patients receiving semaglutide versus 6.1% to 9.2% on placebo, depending on dose [1]. Vomiting occurred in 5% to 9.2% of semaglutide-treated patients. Most GI events were mild to moderate, occurred during dose escalation, and diminished over time. Discontinuation due to GI adverse events ranged from 3.1% to 4.5% across studies.

Pancreatitis

Acute pancreatitis was reported in 0.1% to 0.4% of semaglutide-treated patients across the SUSTAIN program [1]. The label recommends discontinuing Ozempic if pancreatitis is suspected. A 2022 meta-analysis in Diabetes Care pooling data from 76 GLP-1 receptor agonist trials (N=103,371) found no statistically significant increase in pancreatitis risk with GLP-1 RAs versus comparators (OR 0.93, 95% CI 0.65 to 1.34) [12].

Thyroid Safety in Humans

Despite the boxed warning derived from rodent data, human epidemiological evidence has not confirmed an increased risk of medullary thyroid carcinoma. A 2023 cohort study published in The BMJ using French national health insurance data (N=2.5 million GLP-1 RA users) found no statistically significant association between GLP-1 receptor agonist use and thyroid cancer overall, though a signal for all thyroid cancers at 1 to 3 years of use (HR 1.58, 95% CI 1.27 to 1.95) warrants continued monitoring [13].

Diabetic Retinopathy

SUSTAIN-6 identified a higher rate of retinopathy complications with semaglutide (3.0%) versus placebo (1.8%), with an HR of 1.76 (95% CI 1.11 to 2.78) [4]. Subsequent analysis suggested this signal was concentrated in patients with pre-existing retinopathy who experienced rapid HbA1c reductions. The American Diabetes Association's Standards of Care recommend ophthalmologic evaluation before starting GLP-1 RA therapy in patients with known retinopathy [14].

Ongoing Regulatory Developments

Several regulatory actions remain in progress or are expected to shape the Ozempic label in the coming years.

FDA Review of GLP-1 RA Class Labeling

The FDA announced in late 2024 that it would evaluate whether class-wide labeling changes are needed for GLP-1 receptor agonists regarding gallbladder-related events, including cholelithiasis and cholecystitis [11]. The agency's Center for Drug Evaluation and Research (CDER) is reviewing pooled data from all marketed GLP-1 RAs, including Ozempic. A decision is expected by late 2026.

Novo Nordisk Label Expansion Efforts

Novo Nordisk has submitted supplemental applications in multiple jurisdictions to update the Ozempic label with cardiovascular outcome language. The company has stated publicly that it is "working with regulatory authorities to ensure the prescribing information reflects the totality of evidence from the semaglutide clinical program" [15]. Whether the Ozempic label will ultimately carry a cardiovascular risk reduction claim (currently held only by Wegovy at the 2.4 mg dose) depends on each agency's assessment of dose-response extrapolation.

Patent and Exclusivity Considerations

Novo Nordisk holds multiple patents covering the semaglutide molecule, the injection device, and specific formulations. The FDA's Orange Book lists composition-of-matter patents expiring in 2032, with device patents extending further. These exclusivity periods affect when biosimilar or generic semaglutide products might enter the market, a factor that could reshape the regulatory and access picture worldwide.

How Clinicians Should Use the Regulatory Record

The regulatory record is not just paperwork. It tells prescribers exactly what a drug has been proven to do in populations large enough to matter, and what safety signals demand monitoring.

Prescribe Within the Approved Indication

Ozempic is FDA-approved for type 2 diabetes. Off-label prescribing for weight loss (without a diabetes diagnosis) is common, but it lacks the regulatory protections of an approved indication, including the insurance coverage frameworks and post-market monitoring tied to specific NDA-approved uses [1]. Clinicians prescribing off-label should document the rationale and obtain informed consent that addresses the off-label status.

Monitor for Label-Specified Risks

Screen for personal or family history of MTC before initiating therapy. Obtain baseline ophthalmologic evaluation in patients with known diabetic retinopathy. Counsel patients on signs and symptoms of pancreatitis. Report suspected adverse events to the FDA's MedWatch program or the relevant national pharmacovigilance authority.

Track Label Updates

The Ozempic label has been revised multiple times since 2017. Clinicians should periodically review the current prescribing information via DailyMed or Drugs@FDA rather than relying on outdated package inserts. The 2 mg dose approval, ileus warning addition, and evolving cardiovascular language are examples of changes that directly affect prescribing decisions.